SABCS

At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.

Qiagen and Foundation Medicine will develop tissue- and plasma-based companion tests to identify best responders to the PI3K inhibitor alpelisib

The studies involved data from 14,000 Hispanic women and showed the 87-SNP risk score outperformed its 86-SNP score for European women.

A study exploring adjuvant capecitabine in early-stage TNBC failed but researchers are performing genomic analysis on a subset of patients who benefited.

 

New data on Kadcyla and Tecentriq will help doctors further refine precision medicine options for breast cancer patients with unmet needs.

In a Phase III trial, talazoparib-treated patients had a three-month median progression-free survival advantage over patients treated with chemotherapy chosen by their doctors.

At the San Antonio Breast Cancer Symposium, Myriad reported on the ability of its 86 SNP score to predict disease risk for the majority of women of European ancestry.

Grade 3 breast tumors generally have worse prognoses, but SEER data showed that Oncotype DX can identify a large proportion of patients who do well without chemo.

The company has also joined the Cancer Moonshot program, working within its Blood Profiling Atlas Project on pre-analytical variation in molecular tests.

The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests. 

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.